Loteprednol etabonate transmucosal - Kala Pharmaceuticals

Drug Profile

Loteprednol etabonate transmucosal - Kala Pharmaceuticals

Alternative Names: 0.25% LE-MPP; 1% LE-MPP; KPI-121; LE-MPP; Loteprednol etabonate MPP; Loteprednol etabonate mucus-penetrating particles - Kala Pharmaceuticals; MPP-formulated loteprednol etabonate ophthalmic nanosuspension - Kala Pharmaceuticals

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator Kala Pharmaceuticals
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Eye disorder therapies; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dry eyes; Ocular inflammation; Ocular pain
  • Phase II Diabetic macular oedema; Meibomianitis; Retinal vein occlusion

Most Recent Events

  • 15 Jul 2016 CTP 270058 (NCT02819284) updated intro, KDM, deve table, FLSs and HE
  • 22 Jun 2016 Kala Pharmaceuticals plans a phase III trial for Dry eyes in USA (Ophthalmic) (NCT02813265)
  • 01 Jun 2016 Phase-III clinical trials in Dry eyes in USA (Ophthalmic) (NCT02819284)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top